COMMUNIQUÉS West-GlobeNewswire

ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES
29/10/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Idorsia reports accelerating QUVIVIQ growth, advances key value drivers, and reaffirms full-year financial guidance
29/10/2026
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant) sales reached CHF 142 million in the first nine months of 2026, with growth accelerating quarter-on-quarter. Idorsia reaffirms its full-year 2026 [...]
Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialists
29/10/2026
Ad hoc announcement pursuant to Art. 53 LR Dedicated launch capital and shared participation in future revenues create a focused and capital-efficient pathway to realize the potential of TRYVIO/JERAYGO. Idorsia to host [...]
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
29/10/2026
SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)
29/10/2026
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal [...]
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
29/10/2026
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious [...]
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
29/10/2026
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026 PHILADELPHIA, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, [...]
Precipio Announces Q3-2026 Shareholder Update Call
28/10/2026
Conference Call will be held on November 10th, 2026, at 5:00 PM EST NEW HAVEN, Conn., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2026 [...]
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
28/10/2026
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in children [...]
DBV Technologies publie ses résultats financiers du troisième trimestre 2026 et fait le point sur ses activités
28/10/2026
DBV Technologies publie ses résultats financiers du troisième trimestre 2026 et fait le point sur ses activités Dépôt auprès de la FDA américaine de la demande de licence de produit biologique (le « BLA ») pour le patch [...]
LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
28/10/2026
Q3 2026 VIZZ® product sales increased 50% over prior quarter, with strong momentum continuing into Q4 as consumer awareness broadens and telehealth adoption increases Strategic reorganization to prioritize consumer [...]
STERIS Announces Dividend of $0.69 per share
28/10/2026
DUBLIN, IRELAND, Oct. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.69 per share. The dividend is payable on [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28/10/2026
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
28/10/2026
CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
28/10/2026
RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Jushi Holdings Inc. Reports Third Quarter 2026 Financial Results
28/10/2026
Revenue Increased 7% Year-over-Year to $70.5 Million, With Growth Across Wholesale and Retail Channels Wholesale Revenue Increased 40% Year-Over-Year to $9.7 Million, Setting Second Consecutive Quarterly Record Virginia [...]
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
28/10/2026
Published in Nature Communications, the study found a 10-protein signature that outperformed a leading individual ALS biomarker, including in some patients with difficult-to-diagnose presentations Fremont, Calif., Oct. [...]
Teladoc Health Reports Third Quarter 2026 Results
28/10/2026
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2026 (“Third Quarter 2026”). [...]
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
28/10/2026
Rebecca M. Brown, MD, and Kavita Sarin, MD, PhD, will join management to discuss unmet needs and the treatment landscape for NF1-associated cutaneous and plexiform neurofibromas MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum